Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

Single-cell RNA-seq analysis of longitudinal CD4+ T-cell samples reveals cell-type-specific changes during early stages of type 1 diabetes

ABSTRACT: Single-cell RNA sequencing (scRNA-seq) was performed on longitudinal CD4⁺ T-cell samples from 11 children who later developed type 1 diabetes and 11 matched controls. Samples were collected prior to or at the time of type 1 diabetes–specific autoantibody appearance (seroconversion), between ages 3 and 24 months (n = 73 samples). CD4⁺ T cells were isolated and profiled using the 10x Genomics Chromium Single Cell 3′ Reagent Kits v3.1. Individual samples were labeled with unique cell hashing antibodies and pooled into multiplexed runs, with up to 10 samples (from matched case–control pairs) combined per pool. In total, 9 multiplexed pools were processed on Chromium Next GEM Chips, targeting recovery of approximately 20,000 single cells per run (CH_run2-CH_run10). cDNA and hashtag oligo libraries were generated with dual indexing and sequenced on an Illumina NovaSeq 6000. Raw sequencing data were processed with the Cell Ranger pipeline, and computational demultiplexing was performed to assign each cell to its original sample. Downstream analysis identified 10 CD4⁺ T-cell subtypes across ~99,000 high-quality cells. No significant differences in cell-type proportions were observed between case and control pairs at individual time points. However, cell type–specific gene expression changes and enriched pathways were detected in specific cell types in cases. These early transcriptional and regulatory alterations in CD4⁺ T cells provide a valuable resource for understanding disease initiation and developing predictive biomarkers for type 1 diabetes.

INSTRUMENT(S): Illumina NovaSeq 6000

ORGANISM(S): Homo sapiens

SUBMITTER: Rahul Biradar

PROVIDER: E-MTAB-15832 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Similar Datasets

Project description:We demonstrate diverse roles of interferonâgamma (IFN-Î³) in the induction and regulation of immune-mediated inflammation using a transfer model of autoimmune diabetes. The diabetogenic CD4+BDC2.5 (BDC) T cell clone upon transfer into NOD.scid mice induced destruction of islets of Langerhans leading to diabetes. Administration of a neutralizing antibody to IFN-Î³ (H22) resulted in long term protection (LTP) from diabetes, with inflammation but persistence of a significant, albeit decreased numbers of Î²-cells. BDC T cells were a mixture of cells expressing high, intermediate and low levels of the T cell receptor. Clonotype-low BDC T cells were required for LTP. Furthermore, islet infiltrating leukocytes in the LTP mice contained Foxp3+CD4 T cells. Islet inflammation in both diabetic and LTP mice was characterized by heavy infiltration of macrophages. Gene expression profiles indicated that macrophages in diabetic mice were M1-type, while LTP mice contained M2-differentiated. The LTP was abolished if mice were treated with either an antibody depleting CD4 T cells, or a neutralizing antibody to CTLA-4, in this case, only at a late stage. Neutralization of IL-10, TGF-Î², GITR or CD25 had no effect. Transfer of only clonotype-high expressing BDC T cells induced diabetes but in contrast, H22 antibodies did not inhibit diabetes. While clonotype high T cells induced diabetes even when IFN-Î³ was neutralized, paradoxically, there was reduced inflammation and no diabetes if host myeloid cells lacked IFN-Î³ receptor. Hence, using monoclonal CD4 T cells, IFN-Î³ can have a wide diversity of roles, depending on the setting of the immune process. Experiment Overall Design: Pancreatic islets were laser-capture microdissected from mice injected with diabetogenic T cells. One cohort of mice also received injections with anti-interfereon gamma monoclonal antibody, which protected those mice from developing diabetes. RNA prepared from islets was amplified and analyzed by Affymetrix GeneChips. Each GeneChip was prepared from RNA pooled from 5 mice at each timepoint. GeneChips were prepared from RNA extracted at different days following injection of T cells. The following days were assayed day 0 (i.e., untreated), day 3 (for diabetic and protected islets), day 4 (diabetic and protected), day 5 (only for protected, as diabetic islets were too edematous to dissect), day 8 (diabetic and protected).

Project description:Type 1 diabetes is a multigenic disease caused by T-cell mediated destruction of the insulin producing β-cells. Although conventional (targeted) approaches of identifying causative genes have advanced our knowledge of this disease, many questions remain unanswered. Using a whole molecular systems study, we unraveled the genes/molecular pathways that are altered in CD4 T-cells from young NOD mice prior to insulitis (lymphocytic infiltration into the pancreas). Many of the CD4 T-cell altered genes lie within known diabetes susceptibility regions (Idd), including several genes in the diabetes resistance region Idd13 and two genes (Khdrbs1 and Ptp4a2) in the CD4 T-cell diabetogenic activity region Idd9/11. Alterations involved apoptosis/cell proliferation and metabolic pathways (predominant at 2 weeks), inflammation and cell signaling/activation (predominant at 3 weeks), and innate and adaptive immune responses (predominant at 4 weeks). We identified several factors that may regulate these abnormalities: IRF-1, HNF4A, TP53, BCL2L1 (lies within Idd13), IFNG, IL4, IL15, and prostaglandin E2, which were common to all 3 ages; AR and IL6 to 2 and 4 weeks; and Interferon (IFN-I) and IRF-7 to 3 and 4 weeks. Others were unique to the various ages (e. g. MYC, JUN, and APP to 2 weeks; TNF, TGFB1, NFKB, ERK, and p38MAPK to 3 weeks; and IL12 and STAT4 to 4 weeks). Our data suggest that diabetes resistance genes in Idd13 and Idd9/11, and BCL2L1, IL6-AR and IFNG-IRF-1-IFN-I/IRF-7-IL12 pathways play an important role in CD4 T-cells in the early pathogenesis of autoimmune diabetes. Thus, the alternative approach of investigation at the molecular systems level has captured new information, which combined with validation studies, offers the opportunity to test hypotheses on the role played by the genes/molecular pathways identified in this study, to understand better the mechanisms of autoimmune diabetes in CD4 T-cells, and to develop new therapeutic strategies for the disease. CD4 T-cells were purified from spleen leukocytes collected from 2-, 3- and 4-week old NOD mice and two age-matched control strains, NOR, and C57BL/6, (n=5 for each strain and each age group; except NOD2wk). NOR is an insulitis- and diabetes-free control strain that shares shares ~88% of its genome with NOD mice, including the diabetogenic H2g7 MHC haplotype and several important non-MHC T1D susceptibility loci. C57BL/6 is also a diabetes-resitant strain, but it is more genetically distantly related to NOD.

Dataset Information

Single-cell RNA-seq analysis of longitudinal CD4+ T-cell samples reveals cell-type-specific changes during early stages of type 1 diabetes

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets